French pharmaceutical industry association Leem has called for a stop to drug price reductions after the government announced plans to impose price cuts totalling €920m as part of wider plans to reduce social security spending.
French Industry Attacks Price Cut & Drug Shortage Plans
Leem says new stock obligations would add “a new level of complexity”
The French government’s plans for more price cuts and new obligations on manufacturers to avert drug shortages will add another layer of complexity to an already complicated operating environment, says the industry.
More from France
More from Europe
• By
In a historic move for Africa, five products have been backed for approval via a pilot that tested a continental listing process.
• By
Pharmaceutical companies are being encouraged to reach out to NICE in relation to its HTA Innovation Lab, which provides a sandbox environment in which the health technology assessment body can test new methods of evaluating “innovative and disruptive” therapies.
• By
The weight management drug, Mysimba, continues to demonstrate a positive benefit-risk balance but the data available are not sufficient to fully determine the cardiovascular safety beyond 12 months. Meanwhile, Currax this month announced the publication of a peer-reviewed study of Mysimba that followed patients for over 4.7 years and found no evidence of excess cardiovascular risk.